Don’t miss the latest developments in business and finance.

Zydus Cadila receives USFDA approval for Betamethasone Dipropionate Cream

Image
Capital Market
Last Updated : Jan 12 2019 | 3:04 PM IST
Zydus Cadila has received the final approval from the USFDA to market Betamethasone Dipropionate Cream USP (US RLD DIPROLENE AF), 0.05%. It will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

This medication is a strong corticosteroid and is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). Betamethasone reduces the swelling, itching and redness that can occur in these types of conditions.

The group also received a final approval for Amlodipine and Atorvastatin Tablets USP (US RLD Caduet) in the strengths of 2.5 mg/10 mg, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

This combination product contains two active ingredients - amlodipine and atorvastatin. Amlodipine reduces blood pressure and the workload on the heart by relaxing the walls of the blood vessels. It is used to lower blood pressure and to treat angina (chest pain). Atorvastatin is used in combination with diet and exercise to treat high cholesterol. It works by blocking an enzyme that is needed to make cholesterol in the body.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Jan 12 2019 | 2:40 PM IST

Next Story